Diagnostic Imaging, Malignant Lymphoma, Relapsed Hodgkin's Disease, Adult, Relapsed Non Hodgkin Lymphoma
Conditions
Keywords
aggressive non-hodgkin lymphoma, hodgkin lymphoma, FDG-PET/CT, follow-up, routine surveillance
Brief summary
In the study, we aimed to characterize the role of FDG PET/CT surveillance at 12 months of malignant lymphoma in asymptomatic patients after a first complete remission and to define a rational follow-up strategy.
Detailed description
Most aggressive lymphomas are sensitive to first-line immunochemotherapy and are in first Complete Remission (CR) with initial therapy. CR significantly decreases the risk of recurrence and increases survival. However, a cure is not guaranteed and approximately one third of lymphoma patients have a relapse disease. FDG PET/CT is a valuable noninvasive tool in the evaluation of lymphomas, especially to differentiate viable lymphoma and fibrosis or necrosis in residual mass. The majority of relapses are diagnosed based on clinical symptoms reported by patients. And the role of FDG PET/CT for routine surveillance of patients after treatment is controversial. However, many medical centers use routine follow-up FDG PET/CT in addition to physical examination and laboratory analysis to detect subclinical relapse. Thus, we can imagine a good timing to routine FDG PET/CT when the tumor burden is small in the asymptomatic window. Survival improvement for relapse detected by routine follow-up imaging is not clearly established compared to diagnosis by clinical symptoms. Several studies tried to assess the value of follow-up FDG PET/CT but population, type, timing and duration of surveillance imaging was very heterogeneous.
Interventions
None listed
Sponsors
University Hospital, Brest
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
* first diagnosis of aggressive lymphoma, complete metabolic remission after a first-line of chemotherapy, no relapse in the first year after the end of treatment
Exclusion criteria
* minor patient, pregnant woman, legal protection (legal curatorship / guardianship), absence of consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| role of FDG-PET/CT surveillance at 12months of lymphoma in asymptomatic patient in first complete remission | one day | detection rate of relapse at 1 year and at the end of follow-up |
| performances FDG-PET/CT 1 year | one day | sensitivity, sensibility, predictive negative value, predictive positive value, accuracy |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| overall survival and progression-free survival | one day | as the time from the end of first-line chemotherapy |
Outcome results
None listed